<DOC>
	<DOC>NCT01408511</DOC>
	<brief_summary>A multicenter, open-label study to evaluate the adrenal suppression potential of Mapracorat 0.1% ointment in adults with atopic dermatitis.</brief_summary>
	<brief_title>HPA Axis Study in Adults</brief_title>
	<detailed_description>Assessment of safety, efficacy, pharmacokinetics and adrenal suppression potential of Mapracorat 0.1% ointment in adults with atopic dermatitis.</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Signed written informed consent Male or female subject aged &gt;= 18 years Diagnosis of atopic dermatitis according to Hanifin and Rajka Criteria Investigator's Global Assessment (IGA) score of 3 (moderate) to 4 (severe) at baseline Normal ACTH response before start of treatment Pregnancy or lactation Clinically relevant disease, which could interfere with the study conduct or the evaluation and interpretation of the study results Concomitant medical or dermatological disorder(s), which could interfere with the study conduct or the evaluation and interpretation of the study results Clinically manifest immunosuppressive disorder or known history of malignant disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>